Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL27357743 | 0.85 | TSHR (0.53) | TSHRALDH1A1TDP1 | |
| Dimethylformamide SCHEMBL23001593 | 0.81 | TSHR (0.56) | TSHRTDP1 | |
| Dimethylformamide SCHEMBL2145949 | 0.79 | — | — | |
| Acetaldehyde SCHEMBL3120552 | 0.76 | — | — | |
| Dimethylformamide SCHEMBL28224916 | 0.76 | — | — | |
| Dimethylformamide SCHEMBL27730194 | 0.76 | TSHR (0.69) | TSHR | |
| Dimethylformamide SCHEMBL28188620 | 0.75 | — | — | |
| Dimethylformamide SCHEMBL10141201 | 0.75 | — | — | |
| Dimethylformamide SCHEMBL2280000 | 0.75 | — | — | |
| Dimethylformamide SCHEMBL5 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795177-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2019-04-23 | — | — | CN | disclosed |
| CN-103874695-B | 2-pyridyloxy-4-carbonitrile orexin receptor antagonists | 默沙东公司 | 2017-12-15 | — | — | CN | disclosed |
| CN-106795177-A | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-2694512-A1 | CRYSTALLINE AND NON- CRYSTALLINE FORMS OF TOFACITINIB, AND A PHARMACEUTICAL COMPOSITION COMPRISING TOFACITINIB AND A PENETRATION ENHANCER | Pfizer Inc (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012137111-A1 | CRYSTALLINE AND NON- CRYSTALLINE FORMS OF TOFACITINIB, AND A PHARMACEUTICAL COMPOSITION COMPRISING TOFACITINIB AND A PENETRATION ENHANCER | PFIZER INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| CN-102171188-A | Tripyridyl carboxamide orexin receptor antagonists | MERCK & CO INC | 2011-08-31 | — | — | CN | disclosed |
| US-20060247470-A1 | Process for producing optically active carboxylic acid substituted in 2-position | KANEKA CORPORATION | 2006-11-02 | — | — | US | disclosed |
| US-7094926-B2 | Process for producing optically active carboxylic acid substituted in 2-position | KANEKA CORPORATION (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1251115-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID SUBSTITUTED IN 2-POSITION | KANEKA CORPORATION (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247470-A1 | Process for producing optically active carboxylic acid substituted in 2-position | HAO2, CA2, HACL2 | TSHR 1685/4885ALDH1A1 558/4885TDP1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.